Title: HIV & Atherosclerosis
题目：HIV与动脉粥样硬化
Author 作者: Semhar Tewelde
翻译：李 辉 校对：肖 锋

Advances in antiretroviral treatment has increased the life expectancy of patients with HIV significantly, AIDS-related deaths have fallen by 30% since they peaked in 2005.
抗逆转录病毒治疗的进展显著增加了HIV患者的预期寿命，AIDS相关的死亡自从2005年达到高峰后目前已下降了30%。
HIV infection predisposes to a chronic inflammatory and immunologic dysfunctional state, subsequent highly active antiretroviral treatment (HAART) results in metabolic changes and dyslipidemia.
HIV感染使机体倾向于一种慢性炎症及免疫失调状态，随后的高效抗逆转录病毒疗法（HAART）也可导致代谢改变及血脂异常。
In the post-HAART era, CAD is now considered to be the main cause of heart failure in HIV-infected patients, superseding the prior most common etiologies myocarditis and opportunistic infections.
在高效抗逆转录治疗后期，冠状动脉疾病被认为是导致HIV病毒感染患者心的主要原因，已超过以前最常见的病因，心肌炎及机会性感染。
The presentation of CAD in HIV-infected patients is largely similar to that in the general population with the exception is that they present at a younger age.
除年龄小外，冠状动脉疾病在HIV感染患者中的表现与一般人群大致相同，
Certain antiretroviral agents specifically protease inhibitors have conventionally been associated with lipid dysfunction, further complicating the HIV-infected patients milieu.
一些抗逆转录病毒的特异性蛋白酶抑制剂通常与脂质代谢紊乱有关，并使HIV感染患者的病情进一步复杂化。
Recent research has shown that a C-C chemokine receptor-type 5 (CCR5) antagonists has emerged as a potential target both as an antiretroviral agent as well as in the process of arresting atherogenesis, but warrants more research.
最近的研究指出，C-C趋化因子受体5（CCR5）拮抗剂已成为抗逆转录药物治疗以及抗动脉粥样硬化的潜在靶点，但需要更多的研究。
References 参考文献：
Ng B, MacPherson P, et al. Heart failure in HIV infection: focus on the role of atherosclerosis. Current Opinion in Cardiology. Issue: Volume 29(2) pgs. 174-179 March 2014.